Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

Pharmaceutical

Innate Pharma SA

Eric Vivier

Nicola Beltraminelli

Frederic Lombard

Odile Laurent

Yannis Morel

Odile Belzunce

Laure-Hélène Mercier

Henry Wheeler

Claire De Saint Blanquat

Advisory and Governance

Leadership Team

Compliance and Legal

Teams at Innate Pharma SA

Advisory and Governance

Leadership Team

Compliance and Legal